BM-MSCs and AT-MSCs induced a similar decrease in NK cell proliferation and cytokine secretion.

BM-MSCs show higher capacity than AT-MSCs to inhibit NK cell cytotoxic activity but the same susceptibility to NK cell lysis.

AT-MSCs are more potent in inhibiting DC differentiation than BM-MSCs, but both similarly reduced the ability of DCs to induce CD4⁺ T cell proliferation and cytokine production.

BM-MSCs and AT-MSCs induce a similar decrease in T cell proliferation and production of inflammatory cytokines after activation.

MSCs from different donors could exert different immunomodulatory potential on the same receptor.